You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Pharma & Healthcare

Global Cancer Janus Kinase Inhibitors Market Research Report 2021 Professional Edition

Cancer Janus Kinase Inhibitors
The conventional modes of cancer management including surgery, radiotherapy and chemotherapy were discarded as an aspirant for the future of cancer management long back ago. The arrival of modern cancer treatment modalities like immunotherapy and targeted therapy revolutionized the outlook of the future of cancer management. Amongst both of the modern therapies, targeted therapies have shown an impressive growth in a very short duration of time. The targeted therapies developed rapidly and gained much importance in the global market for cancer therapeutics due to their advantages over the conventional therapies. Targeted therapies are safer and more efficient approach for managing cancer. The only drawback for targeted therapies was that only a few targets were available for developing cancer therapeutics. The high efficacy of targeted therapeutics for cancer raised the demand for identifying new targets.
Market Analysis and Insights: Global Cancer Janus Kinase Inhibitors Market
The global Cancer Janus Kinase Inhibitors market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
Global Cancer Janus Kinase Inhibitors Scope and Segment
The global Cancer Janus Kinase Inhibitors market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Cancer Janus Kinase Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
The major regions covered in the report are North America, Europe, Asia-Pacific, South America, Middle East & Africa, etc. The report has specifically covered major countries including U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc. It includes revenue and volume analysis of each region and their respective countries for the forecast years. It also contains country-wise volume and revenue from the year 2016 to 2021. Additionally, it provides the reader with accurate data on volume sales according to the consumption for the same years.
By the product type, the market is primarily split into
Ruxolitinib
Momelotinib
Lestaurtinib
Pacritinib
By the end users/application, this report covers the following segments
Hospitals
Ambulatory Surgical Centers
Others
Competitive Landscape:
The report provides a list of all the key players in the Cancer Janus Kinase Inhibitors market along with a detailed analysis of the strategies, which the companies are adopting. The strategies mainly include new product Developments, research, and Developments, and also provides revenue shares, company overview, and recent company Developments to remain competitive in the market.
The Cancer Janus Kinase Inhibitors key manufacturers in this market include:
Abbott Laboratories
Asana Biosciences
Astra Zeneca
Celon Pharmaceuticals
Dynamic Pharma
Eli Lilly
Gilead Sciences
Hanmi Pharmaceuticals
Incyte
Kyowa Hakko
Moleculin
Pfizer
PIQUR Therapeutics
Portola Pharmaceuticals
S-BIO
1 Cancer Janus Kinase Inhibitors Market Overview
1.1 Cancer Janus Kinase Inhibitors Product Overview
1.2 Cancer Janus Kinase Inhibitors Market Segment by Type
1.2.1 Ruxolitinib
1.2.2 Momelotinib
1.2.3 Lestaurtinib
1.2.4 Pacritinib
1.3 Global Cancer Janus Kinase Inhibitors Market Size by Type
1.3.1 Global Cancer Janus Kinase Inhibitors Market Size Overview by Type (2016-2027)
1.3.2 Global Cancer Janus Kinase Inhibitors Historic Market Size Review by Type (2016-2021)
1.3.2.1 Global Cancer Janus Kinase Inhibitors Sales Breakdown in Volume by Type (2016-2021)
1.3.2.2 Global Cancer Janus Kinase Inhibitors Sales Breakdown in Value by Type (2016-2021)
1.3.2.3 Global Cancer Janus Kinase Inhibitors Average Selling Price (ASP) by Type (2016-2021)
1.3.3 Global Cancer Janus Kinase Inhibitors Forecasted Market Size by Type (2022-2027)
1.3.3.1 Global Cancer Janus Kinase Inhibitors Sales Breakdown in Volume by Type (2022-2027)
1.3.3.2 Global Cancer Janus Kinase Inhibitors Sales Breakdown in Value by Type (2022-2027)
1.3.3.3 Global Cancer Janus Kinase Inhibitors Average Selling Price (ASP) by Type (2022-2027)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Cancer Janus Kinase Inhibitors Sales Breakdown by Type (2016-2021)
1.4.2 Europe Cancer Janus Kinase Inhibitors Sales Breakdown by Type (2016-2021)
1.4.3 Asia-Pacific Cancer Janus Kinase Inhibitors Sales Breakdown by Type (2016-2021)
1.4.4 Latin America Cancer Janus Kinase Inhibitors Sales Breakdown by Type (2016-2021)
1.4.5 Middle East and Africa Cancer Janus Kinase Inhibitors Sales Breakdown by Type (2016-2021)

2 Global Cancer Janus Kinase Inhibitors Market Competition by Company
2.1 Global Top Players by Cancer Janus Kinase Inhibitors Sales (2016-2021)
2.2 Global Top Players by Cancer Janus Kinase Inhibitors Revenue (2016-2021)
2.3 Global Top Players Cancer Janus Kinase Inhibitors Price (2016-2021)
2.4 Global Top Manufacturers Cancer Janus Kinase Inhibitors Manufacturing Base Distribution, Sales Area, Product Type
2.5 Cancer Janus Kinase Inhibitors Market Competitive Situation and Trends
2.5.1 Cancer Janus Kinase Inhibitors Market Concentration Rate (2016-2021)
2.5.2 Global 5 and 10 Largest Manufacturers by Cancer Janus Kinase Inhibitors Sales and Revenue in 2020
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Cancer Janus Kinase Inhibitors as of 2020)
2.7 Date of Key Manufacturers Enter into Cancer Janus Kinase Inhibitors Market
2.8 Key Manufacturers Cancer Janus Kinase Inhibitors Product Offered
2.9 Mergers & Acquisitions, Expansion

3 Cancer Janus Kinase Inhibitors Status and Outlook by Region
3.1 Global Cancer Janus Kinase Inhibitors Market Size and CAGR by Region: 2016 VS 2021 VS 2026
3.2 Global Cancer Janus Kinase Inhibitors Historic Market Size by Region
3.2.1 Global Cancer Janus Kinase Inhibitors Sales in Volume by Region (2016-2021)
3.2.2 Global Cancer Janus Kinase Inhibitors Sales in Value by Region (2016-2021)
3.2.3 Global Cancer Janus Kinase Inhibitors Sales (Volume & Value) Price and Gross Margin (2016-2021)
3.3 Global Cancer Janus Kinase Inhibitors Forecasted Market Size by Region
3.3.1 Global Cancer Janus Kinase Inhibitors Sales in Volume by Region (2022-2027)
3.3.2 Global Cancer Janus Kinase Inhibitors Sales in Value by Region (2022-2027)
3.3.3 Global Cancer Janus Kinase Inhibitors Sales (Volume & Value), Price and Gross Margin (2022-2027)

4 Global Cancer Janus Kinase Inhibitors by Application
4.1 Cancer Janus Kinase Inhibitors Market Segment by Application
4.1.1 Hospitals
4.1.2 Ambulatory Surgical Centers
4.1.3 Others
4.2 Global Cancer Janus Kinase Inhibitors Market Size by Application
4.2.1 Global Cancer Janus Kinase Inhibitors Market Size Overview by Application (2016-2027)
4.2.2 Global Cancer Janus Kinase Inhibitors Historic Market Size Review by Application (2016-2021)
4.2.2.1 Global Cancer Janus Kinase Inhibitors Sales Breakdown in Volume, by Application (2016-2021)
4.2.2.2 Global Cancer Janus Kinase Inhibitors Sales Breakdown in Value, by Application (2016-2021)
4.2.2.3 Global Cancer Janus Kinase Inhibitors Average Selling Price (ASP) by Application (2016-2021)
4.2.3 Global Cancer Janus Kinase Inhibitors Forecasted Market Size by Application (2022-2027)
4.2.3.1 Global Cancer Janus Kinase Inhibitors Sales Breakdown in Volume, by Application (2022-2027)
4.2.3.2 Global Cancer Janus Kinase Inhibitors Sales Breakdown in Value, by Application (2022-2027)
4.2.3.3 Global Cancer Janus Kinase Inhibitors Average Selling Price (ASP) by Application (2022-2027)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Cancer Janus Kinase Inhibitors Sales Breakdown by Application (2016-2021)
4.3.2 Europe Cancer Janus Kinase Inhibitors Sales Breakdown by Application (2016-2021)
4.3.3 Asia-Pacific Cancer Janus Kinase Inhibitors Sales Breakdown by Application (2016-2021)
4.3.4 Latin America Cancer Janus Kinase Inhibitors Sales Breakdown by Application (2016-2021)
4.3.5 Middle East and Africa Cancer Janus Kinase Inhibitors Sales Breakdown by Application (2016-2021)

5 North America Cancer Janus Kinase Inhibitors by Country
5.1 North America Cancer Janus Kinase Inhibitors Historic Market Size by Country
5.1.1 North America Cancer Janus Kinase Inhibitors Sales in Volume by Country (2016-2021)
5.1.2 North America Cancer Janus Kinase Inhibitors Sales in Value by Country (2016-2021)
5.2 North America Cancer Janus Kinase Inhibitors Forecasted Market Size by Country
5.2.1 North America Cancer Janus Kinase Inhibitors Sales in Volume by Country (2022-2027)
5.2.2 North America Cancer Janus Kinase Inhibitors Sales in Value by Country (2022-2027)

6 Europe Cancer Janus Kinase Inhibitors by Country
6.1 Europe Cancer Janus Kinase Inhibitors Historic Market Size by Country
6.1.1 Europe Cancer Janus Kinase Inhibitors Sales in Volume by Country (2016-2021)
6.1.2 Europe Cancer Janus Kinase Inhibitors Sales in Value by Country (2016-2021)
6.2 Europe Cancer Janus Kinase Inhibitors Forecasted Market Size by Country
6.2.1 Europe Cancer Janus Kinase Inhibitors Sales in Volume by Country (2022-2027)
6.2.2 Europe Cancer Janus Kinase Inhibitors Sales in Value by Country (2022-2027)

7 Asia-Pacific Cancer Janus Kinase Inhibitors by Region
7.1 Asia-Pacific Cancer Janus Kinase Inhibitors Historic Market Size by Region
7.1.1 Asia-Pacific Cancer Janus Kinase Inhibitors Sales in Volume by Region (2016-2021)
7.1.2 Asia-Pacific Cancer Janus Kinase Inhibitors Sales in Value by Region (2016-2021)
7.2 Asia-Pacific Cancer Janus Kinase Inhibitors Forecasted Market Size by Region
7.2.1 Asia-Pacific Cancer Janus Kinase Inhibitors Sales in Volume by Region (2022-2027)
7.2.2 Asia-Pacific Cancer Janus Kinase Inhibitors Sales in Value by Region (2022-2027)

8 Latin America Cancer Janus Kinase Inhibitors by Country
8.1 Latin America Cancer Janus Kinase Inhibitors Historic Market Size by Country
8.1.1 Latin America Cancer Janus Kinase Inhibitors Sales in Volume by Country (2016-2021)
8.1.2 Latin America Cancer Janus Kinase Inhibitors Sales in Value by Country (2016-2021)
8.2 Latin America Cancer Janus Kinase Inhibitors Forecasted Market Size by Country
8.2.1 Latin America Cancer Janus Kinase Inhibitors Sales in Volume by Country (2022-2027)
8.2.2 Latin America Cancer Janus Kinase Inhibitors Sales in Value by Country (2022-2027)

9 Middle East and Africa Cancer Janus Kinase Inhibitors by Country
9.1 Middle East and Africa Cancer Janus Kinase Inhibitors Historic Market Size by Country
9.1.1 Middle East and Africa Cancer Janus Kinase Inhibitors Sales in Volume by Country (2016-2021)
9.1.2 Middle East and Africa Cancer Janus Kinase Inhibitors Sales in Value by Country (2016-2021)
9.2 Middle East and Africa Cancer Janus Kinase Inhibitors Forecasted Market Size by Country
9.2.1 Middle East and Africa Cancer Janus Kinase Inhibitors Sales in Volume by Country (2022-2027)
9.2.2 Middle East and Africa Cancer Janus Kinase Inhibitors Sales in Value by Country (2022-2027)

10 Company Profiles and Key Figures in Cancer Janus Kinase Inhibitors Business
10.1 Abbott Laboratories
10.1.1 Abbott Laboratories Corporation Information
10.1.2 Abbott Laboratories Introduction and Business Overview
10.1.3 Abbott Laboratories Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.1.4 Abbott Laboratories Cancer Janus Kinase Inhibitors Products Offered
10.1.5 Abbott Laboratories Recent Development
10.2 Asana Biosciences
10.2.1 Asana Biosciences Corporation Information
10.2.2 Asana Biosciences Introduction and Business Overview
10.2.3 Asana Biosciences Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.2.4 Abbott Laboratories Cancer Janus Kinase Inhibitors Products Offered
10.2.5 Asana Biosciences Recent Development
10.3 Astra Zeneca
10.3.1 Astra Zeneca Corporation Information
10.3.2 Astra Zeneca Introduction and Business Overview
10.3.3 Astra Zeneca Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.3.4 Astra Zeneca Cancer Janus Kinase Inhibitors Products Offered
10.3.5 Astra Zeneca Recent Development
10.4 Celon Pharmaceuticals
10.4.1 Celon Pharmaceuticals Corporation Information
10.4.2 Celon Pharmaceuticals Introduction and Business Overview
10.4.3 Celon Pharmaceuticals Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.4.4 Celon Pharmaceuticals Cancer Janus Kinase Inhibitors Products Offered
10.4.5 Celon Pharmaceuticals Recent Development
10.5 Dynamic Pharma
10.5.1 Dynamic Pharma Corporation Information
10.5.2 Dynamic Pharma Introduction and Business Overview
10.5.3 Dynamic Pharma Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.5.4 Dynamic Pharma Cancer Janus Kinase Inhibitors Products Offered
10.5.5 Dynamic Pharma Recent Development
10.6 Eli Lilly
10.6.1 Eli Lilly Corporation Information
10.6.2 Eli Lilly Introduction and Business Overview
10.6.3 Eli Lilly Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.6.4 Eli Lilly Cancer Janus Kinase Inhibitors Products Offered
10.6.5 Eli Lilly Recent Development
10.7 Gilead Sciences
10.7.1 Gilead Sciences Corporation Information
10.7.2 Gilead Sciences Introduction and Business Overview
10.7.3 Gilead Sciences Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.7.4 Gilead Sciences Cancer Janus Kinase Inhibitors Products Offered
10.7.5 Gilead Sciences Recent Development
10.8 Hanmi Pharmaceuticals
10.8.1 Hanmi Pharmaceuticals Corporation Information
10.8.2 Hanmi Pharmaceuticals Introduction and Business Overview
10.8.3 Hanmi Pharmaceuticals Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.8.4 Hanmi Pharmaceuticals Cancer Janus Kinase Inhibitors Products Offered
10.8.5 Hanmi Pharmaceuticals Recent Development
10.9 Incyte
10.9.1 Incyte Corporation Information
10.9.2 Incyte Introduction and Business Overview
10.9.3 Incyte Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.9.4 Incyte Cancer Janus Kinase Inhibitors Products Offered
10.9.5 Incyte Recent Development
10.10 Kyowa Hakko
10.10.1 Company Basic Information, Manufacturing Base and Competitors
10.10.2 Cancer Janus Kinase Inhibitors Product Category, Application and Specification
10.10.3 Kyowa Hakko Cancer Janus Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2016-2021)
10.10.4 Main Business Overview
10.10.5 Kyowa Hakko Recent Development
10.11 Moleculin
10.11.1 Moleculin Corporation Information
10.11.2 Moleculin Introduction and Business Overview
10.11.3 Moleculin Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.11.4 Moleculin Cancer Janus Kinase Inhibitors Products Offered
10.11.5 Moleculin Recent Development
10.12 Pfizer
10.12.1 Pfizer Corporation Information
10.12.2 Pfizer Introduction and Business Overview
10.12.3 Pfizer Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.12.4 Pfizer Cancer Janus Kinase Inhibitors Products Offered
10.12.5 Pfizer Recent Development
10.13 PIQUR Therapeutics
10.13.1 PIQUR Therapeutics Corporation Information
10.13.2 PIQUR Therapeutics Introduction and Business Overview
10.13.3 PIQUR Therapeutics Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.13.4 PIQUR Therapeutics Cancer Janus Kinase Inhibitors Products Offered
10.13.5 PIQUR Therapeutics Recent Development
10.14 Portola Pharmaceuticals
10.14.1 Portola Pharmaceuticals Corporation Information
10.14.2 Portola Pharmaceuticals Introduction and Business Overview
10.14.3 Portola Pharmaceuticals Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.14.4 Portola Pharmaceuticals Cancer Janus Kinase Inhibitors Products Offered
10.14.5 Portola Pharmaceuticals Recent Development
10.15 S-BIO
10.15.1 S-BIO Corporation Information
10.15.2 S-BIO Introduction and Business Overview
10.15.3 S-BIO Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.15.4 S-BIO Cancer Janus Kinase Inhibitors Products Offered
10.15.5 S-BIO Recent Development

11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Cancer Janus Kinase Inhibitors Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Cancer Janus Kinase Inhibitors Industrial Chain Analysis
11.4 Cancer Janus Kinase Inhibitors Market Dynamics
11.4.1 Industry Trends
11.4.2 Market Drivers
11.4.3 Market Challenges
11.4.4 Market Restraints

12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Cancer Janus Kinase Inhibitors Distributors
12.3 Cancer Janus Kinase Inhibitors Downstream Customers

13 Research Findings and Conclusion

14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
  • FORMAT: PDF
  • PUBLISHED DATE: Jun, 2021
  • NO OF PAGES: 140